Natco Pharma, one of the few Indian companies to venture into new drug discovery research, witnessed a rise in share price on Wednesday after it announced that it has filed Abbreviated New Drug Applications (ANDAs) for Fingolimod, 0.5mg Capsules & Cabazitaxel, 60mg/1.5ml Injection, with the U.S. Federal Drug Administration (USFDA), through its respective marketing partners in the USA.

Natco & its associated marketing partners for the above products in the USA, believe that they are the first company to have filed a substantially complete ANDA which includes a paragraph IV certification for Fingolimod, 0.5mg Capsules & Cabazitaxel, 60mg/1.5ml Injection, providing 180 days of marketing exclusivity upon its final USFDA approval.

Shares of the company are trading at Rs 1,449.85, up Rs 15.7, or 1.09% at the Bombay Stock Exchange (BSE) on Wednesday at 11:27 a.m.

The scrip has touched an intra-day high of Rs 1,469 and low of Rs 1,423. The total volume of shares traded at the BSE is 5,005.